36.46
+0.08%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Pacira Biosciences
From its filings with the US Securities and Exchange Commission
Pacira Biosciences is based in Brisbane, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker PCRX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $726.4m and net income of $7.0m. At that date it held total assets of $1.26bn and shareholders' equity of $693.1m.
We were incorporated in Delaware under the name Blue Acquisition Corp. in December 2006 and changed our name to Pacira, Inc. in June 2007. In October 2010, we changed our name to Pacira Pharmaceuticals, Inc. and in April 2019, we changed our name to Pacira BioSciences, Inc. Our principal executive offices and corporate headquarters are located in Brisbane, California.
Pacira®, EXPAREL®, ZILRETTA®, iovera®°, the Pacira logo and other trademarks or service marks of Pacira appearing in this Annual Report are the property of Pacira, and when first used in each part of this Annual Report, include the ® symbol.
This Annual Report contains additional trade names, trademarks and service marks of other companies, which may or may not appear with the ® or ™ symbol. The absence of these symbols does not in any way imply that the respective owner(s) will not assert their rights to such marks to the fullest extent under applicable law. Our use of trademarks or trade names of other companies should not suggest any endorsement, sponsorship or other relationship with or by such companies.
Our mission is to deliver innovative, non-opioid pain therapies to transform the lives of patients. We have three commercialized non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) and iovera®°. EXPAREL—our flagship product—is a long-acting, local analgesic currently approved for postsurgical pain management.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 3 Feb 2011
- Employees
- 825
- Website
- pacira.com ↗
- Head office
- 2000 SIERRA POINT PARKWAY, BRISBANE, CA, 94005
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Ms. Laura BregeIndependent Chairman of the Board$389,005
- Mr. Frank LeeChief Executive Officer, Director, since 2024$15.9m
- Mr. Shawn CrossChief Financial Officer$1.4m
- Mr. Daryl GauglerExecutive Vice President - Commercial Operations$3.6m
- Ms. Lauren RikerSenior Vice President - Finance, Principal Accounting Officer$1.4m
- Ms. Kristen WilliamsChief Administrative Officer, Secretary$3.6m
- Ms. Krys CorbettChief Business Officer
- Dr. Jonathan SloninChief Medical Officer$2.9m
- Mr. Brendan TeehanChief Commercial Officer
- Dr. Marcelo BigalIndependent Director$365,434
- Mr. Abraham CeesayIndependent Director$362,005
- Gov. Christopher ChristieIndependent Director$350,005
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 42
- Environment
- 22
- Social
- 64
- Governance
- 41
- Women in the workforce
- 42%
- Carbon reduction policy
- No
- Human rights policy
- Yes
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.